Differences in Associations of Antidepressants and Hospitalization Due to Hyponatremia - 08/12/17

Abstract |
Background |
Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants are important as a cause of hyponatremia. However, most studies have focused on the effect on sodium levels regardless of clinical symptoms, or have been too small to be able to discriminate between the effects of specific antidepressant drugs. The objective of the present study was to investigate the association between different groups of antidepressants and the risk of hospitalization due to hyponatremia.
Methods |
In this register-based case-control study of patients in the general Swedish population, we identified 14,359 individuals with a main diagnosis of hyponatremia. For every case, 4 matched controls were included (n = 57,382). To investigate the temporal aspects of drug-induced hyponatremia, antidepressant exposure was divided into patients with newly initiated and ongoing treatment. Univariable and multivariable logistic regression was used to analyze the association of antidepressant use and hospitalization.
Results |
For newly initiated antidepressants, adjusted odds ratios (95% confidence interval) for a main diagnosis of hyponatremia compared with controls were: citalopram 5.50 (4.71-6.44); sertraline 4.96 (3.81-6.48); venlafaxine 5.28 (3.20-8.83); tricyclic antidepressants 1.59 (1.13-2.24); and mirtazapine 2.54 (2.04-3.16). Adjusted odds ratio (confidence interval) for individuals with ongoing treatment ranged from 0.57 (0.52-0.63) for citalopram to 1.08 (0.85-1.36) for other SSRIs.
Conclusions |
There was a strong association between newly initiated treatment with SSRIs or venlafaxine and hospitalization due to hyponatremia. The association for tricyclic antidepressants and mirtazapine was small to moderate. In contrast, there was no evidence that ongoing treatment with antidepressants increases the risk for hospitalization due to hyponatremia.
El texto completo de este artículo está disponible en PDF.Keywords : Antidepressants, Hyponatremia, Selective serotonin reuptake inhibitors, SIADH
Esquema
| Funding: The cost for retrieval of the data was funded by a clinical trial investigating the effect of c-peptide for the Development of Diabetic Neuropathy sponsored by Cebix Incorporated (Grant Number: CBX12980-DN201X). |
|
| Conflicts of Interest: Drs. Jakob Skov and Buster Mannheimer report personal fees from Otsuka Pharma Scandinavia AB, outside the submitted work. No other authors had any conflicts of interest. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 131 - N° 1
P. 56-63 - janvier 2018 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
